标题
Triple-negative breast cancer: are we making headway at least?
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 4, Issue 4, Pages 195-210
出版商
SAGE Publications
发表日期
2012-05-01
DOI
10.1177/1758834012444711
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors
- (2017) J. J. Mahany et al. JOURNAL OF CLINICAL ONCOLOGY
- First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors
- (2017) S. Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
- (2017) S. J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
- (2017) R. A. Dent et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).
- (2017) K. L. Tedesco et al. JOURNAL OF CLINICAL ONCOLOGY
- Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.
- (2017) K. A. Gelmon et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
- (2012) Siker Kimbung et al. CANCER LETTERS
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer
- (2011) H Joensuu et al. CANCER RESEARCH
- Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
- (2011) J O'Shaughnessy et al. CANCER RESEARCH
- 801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted Agents
- (2011) M. Arnedos et al. EUROPEAN JOURNAL OF CANCER
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
- (2011) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of personalized medicine—perspective from a cancer center
- (2011) Thomas Tursz et al. Nature Reviews Clinical Oncology
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Stratification of Triple-Negative Breast Cancers
- (2011) C. M. Perou ONCOLOGIST
- Treatment of HER2-overexpressing breast cancer
- (2010) J. Baselga ANNALS OF ONCOLOGY
- Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
- (2010) Jens Huober et al. BREAST CANCER RESEARCH AND TREATMENT
- Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
- (2010) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).
- (2010) W. Gradishar et al. CANCER RESEARCH
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
- (2010) A. Brufsky et al. CANCER RESEARCH
- SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).
- (2010) J. Baselga et al. CANCER RESEARCH
- Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC).
- (2010) C. Barrios et al. CANCER RESEARCH
- Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).
- (2010) J. O'Shaughnessy et al. CANCER RESEARCH
- Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
- (2010) S. Y. Park et al. CLINICAL CANCER RESEARCH
- Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study
- (2010) Qing Zeng et al. EUROPEAN JOURNAL OF CANCER
- Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations
- (2010) Gunda Pristauz et al. HISTOPATHOLOGY
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas)
- (2010) C. Marchio et al. JOURNAL OF CLINICAL PATHOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
- (2010) Felipe C Geyer et al. MODERN PATHOLOGY
- Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer
- (2010) Miguel Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
- (2010) J. Lehmann-Che et al. ONCOLOGIST
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
- (2009) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
- (2009) E. Bolderson et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
- (2009) F. Andre et al. CLINICAL CANCER RESEARCH
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
- (2009) Judith Hugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
- (2009) Leo A Niemeier et al. MODERN PATHOLOGY
- Platinum-based chemotherapy in triple-negative breast cancer
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- Pattern of metastatic spread in triple-negative breast cancer
- (2008) Rebecca Dent et al. BREAST CANCER RESEARCH AND TREATMENT
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
- (2008) Giuseppe Viale et al. BREAST CANCER RESEARCH AND TREATMENT
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer
- (2008) Nancy U. Lin et al. CANCER
- Therapeutic Strategies for Triple-Negative Breast Cancer
- (2008) Antoinette R. Tan et al. CANCER JOURNAL
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
- (2008) M. C.U. Cheang et al. CLINICAL CANCER RESEARCH
- DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy
- (2008) S. Ashwell et al. CLINICAL CANCER RESEARCH
- Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
- (2008) Susan Ashwell et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype
- (2008) David Voduc et al. HUMAN PATHOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum
- (2008) Marick Laé et al. MODERN PATHOLOGY
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- Triple-negative/basal-like breast cancer: review
- (2008) Emad A. Rakha et al. PATHOLOGY
- HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
- (2007) Alessandra Gennari et al. JNCI-Journal of the National Cancer Institute
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started